CagriSema confers ‘high magnitude’ of HbA1c, weight reductions in type 2 diabetes

medpagetoday.com·Jun 8, 2026 · 16 h fa

GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials

morningstar.com·Jun 7, 2026 · 1 g fa

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

morningstar.com·Jun 7, 2026 · 1 g fa

Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

morningstar.com·Jun 6, 2026 · 2 g fa

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more likely to achieve greater than 5% weight loss than those who were switched to tirzepatide, in real-world data

benzinga.com·Jun 8, 2026 · 17 h fa

Novo Nordisk Highlights Positive Weight-Loss Data Across Multiple Programs - Novo Nordisk (NYSE:NVO)

adnkronos.com·Jun 4, 2026 · 5 g fa

ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

morningstar.com·Jun 7, 2026 · 1 g fa

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

morningstar.com·Jun 6, 2026 · 3 g fa

Novo Nordisk's investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes—presented at ADA 2026

economictimes.indiatimes.com·Jun 3, 2026 · 6 g fa

Zydus Semaglutide approval: Delhi HC directs CDSCO to decide on patient safety concerns

benzinga.com·Jun 8, 2026 · 21 h fa

Novo Nordisk CEO Hints Semaglutide Could Be More Than Weight-Loss Drug - Novo Nordisk (NYSE:NVO)